APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections

Compare research editions
View pricing & licenses

Selected research

Industry Research

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Research Report 2026

31 December 2025126 pages

Choose your research edition.

Industry ResearchVancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections include Eli Lily, Wockhardt Ltd, Therapeutic Systems Research Laboratories Inc, TGV-Inhalonix Inc, Roivant Sciences Ltd, Lysimmune BioScience, Destiny Pharma Plc, Debiopharm International SA and CrystalGenomics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market by Company

Eli Lily

Wockhardt Ltd

Therapeutic Systems Research Laboratories Inc

TGV-Inhalonix Inc

Roivant Sciences Ltd

Lysimmune BioScience

Destiny Pharma Plc

Debiopharm International SA

CrystalGenomics Inc

Amprologix Ltd

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Type

Injection

Pills

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Application

Hospital

Clinic

Other

Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Manufacturers (2021-2026) Table 8. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue of Manufacturers (2021-2026) Table 9. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, Product Type & Application Table 14. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Eli Lily Company Information Table 19. Eli Lily Business Overview Table 20. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 22. Eli Lily Recent Developments Table 23. Wockhardt Ltd Company Information Table 24. Wockhardt Ltd Business Overview Table 25. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 27. Wockhardt Ltd Recent Developments Table 28. Therapeutic Systems Research Laboratories Inc Company Information Table 29. Therapeutic Systems Research Laboratories Inc Business Overview Table 30. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 32. Therapeutic Systems Research Laboratories Inc Recent Developments Table 33. TGV-Inhalonix Inc Company Information Table 34. TGV-Inhalonix Inc Business Overview Table 35. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 37. TGV-Inhalonix Inc Recent Developments Table 38. Roivant Sciences Ltd Company Information Table 39. Roivant Sciences Ltd Business Overview Table 40. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 42. Roivant Sciences Ltd Recent Developments Table 43. Lysimmune BioScience Company Information Table 44. Lysimmune BioScience Business Overview Table 45. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 47. Lysimmune BioScience Recent Developments Table 48. Destiny Pharma Plc Company Information Table 49. Destiny Pharma Plc Business Overview Table 50. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 52. Destiny Pharma Plc Recent Developments Table 53. Debiopharm International SA Company Information Table 54. Debiopharm International SA Business Overview Table 55. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 57. Debiopharm International SA Recent Developments Table 58. CrystalGenomics Inc Company Information Table 59. CrystalGenomics Inc Business Overview Table 60. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 62. CrystalGenomics Inc Recent Developments Table 63. Amprologix Ltd Company Information Table 64. Amprologix Ltd Business Overview Table 65. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio Table 67. Amprologix Ltd Recent Developments Table 68. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 69. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2021-2026) & (K Units) Table 70. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region (2021-2026) Table 71. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region (2027-2032) & (K Units) Table 72. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Region (2027-2032) Table 73. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region (2021-2026) & (US$ Million) Table 74. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Region (2021-2026) Table 75. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region (2027-2032) & (US$ Million) Table 76. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Region (2027-2032) Table 77. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 79. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2027-2032) & (K Units) Table 80. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2027-2032) & (US$ Million) Table 82. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 84. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2027-2032) & (K Units) Table 85. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2026) & (US$ Million) Table 86. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2027-2032) & (US$ Million) Table 87. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 89. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2027-2032) & (K Units) Table 90. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2026) & (US$ Million) Table 91. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2027-2032) & (US$ Million) Table 92. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 94. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2027-2032) & (K Units) Table 95. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2026) & (US$ Million) Table 96. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2027-2032) & (US$ Million) Table 97. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2026) & (K Units) Table 99. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2027-2032) & (K Units) Table 100. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2026) & (US$ Million) Table 101. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2027-2032) & (US$ Million) Table 102. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2026) & (K Units) Table 103. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2027-2032) & (K Units) Table 104. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2021-2026) Table 105. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2027-2032) Table 106. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2026) & (US$ Million) Table 107. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2027-2032) & (US$ Million) Table 108. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2021-2026) Table 109. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2027-2032) Table 110. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2021-2026) & (US$/Unit) Table 111. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2027-2032) & (US$/Unit) Table 112. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2026) & (K Units) Table 113. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2027-2032) & (K Units) Table 114. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2021-2026) Table 115. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2027-2032) Table 116. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2026) & (US$ Million) Table 117. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2027-2032) & (US$ Million) Table 118. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Application (2021-2026) Table 119. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Application (2027-2032) Table 120. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2021-2026) & (US$/Unit) Table 121. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2027-2032) & (US$/Unit) Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Distributors List Table 125. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Customers List Table 126. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Trends Table 127. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Drivers Table 128. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Restraints Table 129. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Image Figure 5. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2021-2032) & (US$ Million) Figure 7. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (2021-2032) & (K Units) Figure 8. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Average Price (US$/Unit) & (2021-2032) Figure 9. Injection Product Image Figure 10. Pills Product Image Figure 11. Hospital Product Image Figure 12. Clinic Product Image Figure 13. Other Product Image Figure 14. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region in 2025 Figure 20. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region in 2025 Figure 21. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country in 2025 Figure 22. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2032) Figure 23. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Country (2021-2032) Figure 24. United States Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country in 2025 Figure 27. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2032) Figure 28. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Country (2021-2032) Figure 29. Germany Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. France Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. U.K. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Italy Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Netherlands Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Nordic Countries Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country in 2025 Figure 36. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2032) Figure 37. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Country (2021-2032) Figure 38. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Japan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. South Korea Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. India Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Australia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. China Taiwan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country in 2025 Figure 47. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2032) Figure 48. South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Country (2021-2032) Figure 49. Mexico Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Brazil Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Argentina Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country in 2025 Figure 53. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Country (2021-2032) Figure 54. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Country (2021-2032) Figure 55. Turkey Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Saudi Arabia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. UAE Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2021-2032) Figure 59. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2021-2032) Figure 60. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price (US$/Unit) by Type (2021-2032) Figure 61. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2021-2032) Figure 62. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Application (2021-2032) Figure 63. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price (US$/Unit) by Application (2021-2032) Figure 64. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Value Chain Figure 65. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Production Mode & Process Figure 66. Direct Comparison with Distribution Share Figure 67. Distributors Profiles Figure 68. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Opportunities and Challenges

Scope & coverage.

Types
  • Injection
  • Pills
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Eli Lily
  • Wockhardt Ltd
  • Therapeutic Systems Research Laboratories Inc
  • TGV-Inhalonix Inc
  • Roivant Sciences Ltd
  • Lysimmune BioScience
  • Destiny Pharma Plc
  • Debiopharm International SA
  • CrystalGenomics Inc
  • Amprologix Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2021-2032)
  4. 2.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (2021-2032)
  5. 2.2.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Average Price (2021-2032)
  6. 2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Injection
  9. 2.3.3 Pills
  10. 2.4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital
  13. 2.4.3 Clinic
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, Product Type & Application
  8. 3.8 Global Manufacturers of Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections, Established Date
  9. 3.9 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Eli Lily
  2. 4.1.1 Eli Lily Company Information
  3. 4.1.2 Eli Lily Business Overview
  4. 4.1.3 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  6. 4.1.5 Eli Lily Recent Developments
  7. 4.2 Wockhardt Ltd
  8. 4.2.1 Wockhardt Ltd Company Information
  9. 4.2.2 Wockhardt Ltd Business Overview
  10. 4.2.3 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  12. 4.2.5 Wockhardt Ltd Recent Developments
  13. 4.3 Therapeutic Systems Research Laboratories Inc
  14. 4.3.1 Therapeutic Systems Research Laboratories Inc Company Information
  15. 4.3.2 Therapeutic Systems Research Laboratories Inc Business Overview
  16. 4.3.3 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  18. 4.3.5 Therapeutic Systems Research Laboratories Inc Recent Developments
  19. 4.4 TGV-Inhalonix Inc
  20. 4.4.1 TGV-Inhalonix Inc Company Information
  21. 4.4.2 TGV-Inhalonix Inc Business Overview
  22. 4.4.3 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  24. 4.4.5 TGV-Inhalonix Inc Recent Developments
  25. 4.5 Roivant Sciences Ltd
  26. 4.5.1 Roivant Sciences Ltd Company Information
  27. 4.5.2 Roivant Sciences Ltd Business Overview
  28. 4.5.3 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  30. 4.5.5 Roivant Sciences Ltd Recent Developments
  31. 4.6 Lysimmune BioScience
  32. 4.6.1 Lysimmune BioScience Company Information
  33. 4.6.2 Lysimmune BioScience Business Overview
  34. 4.6.3 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  36. 4.6.5 Lysimmune BioScience Recent Developments
  37. 4.7 Destiny Pharma Plc
  38. 4.7.1 Destiny Pharma Plc Company Information
  39. 4.7.2 Destiny Pharma Plc Business Overview
  40. 4.7.3 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  42. 4.7.5 Destiny Pharma Plc Recent Developments
  43. 4.8 Debiopharm International SA
  44. 4.8.1 Debiopharm International SA Company Information
  45. 4.8.2 Debiopharm International SA Business Overview
  46. 4.8.3 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  48. 4.8.5 Debiopharm International SA Recent Developments
  49. 4.9 CrystalGenomics Inc
  50. 4.9.1 CrystalGenomics Inc Company Information
  51. 4.9.2 CrystalGenomics Inc Business Overview
  52. 4.9.3 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  54. 4.9.5 CrystalGenomics Inc Recent Developments
  55. 4.10 Amprologix Ltd
  56. 4.10.1 Amprologix Ltd Company Information
  57. 4.10.2 Amprologix Ltd Business Overview
  58. 4.10.3 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Portfolio
  60. 4.10.5 Amprologix Ltd Recent Developments
5 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Scenario by Region
  1. 5.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region: 2021-2032
  3. 5.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region: 2021-2026
  4. 5.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Region: 2027-2032
  5. 5.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region: 2021-2032
  6. 5.3.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region: 2021-2026
  7. 5.3.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Region: 2027-2032
  8. 5.4 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Facts & Figures by Country
  9. 5.4.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2032)
  11. 5.4.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Facts & Figures by Country
  15. 5.5.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2032)
  17. 5.5.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Facts & Figures by Country
  36. 5.7.1 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2032)
  38. 5.7.3 South America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.8 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2032)
  2. 6.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Type (2021-2032)
  4. 6.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Type (2021-2032)
  5. 6.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2032)
  2. 7.1.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Market Share by Application (2021-2032)
  4. 7.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Application (2021-2032)
  5. 7.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Value Chain Analysis
  2. 8.1.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Production Mode & Process
  5. 8.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Distributors
  8. 8.2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Customers
9 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Analyzing Market Dynamics
  1. 9.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Trends
  2. 9.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Drivers
  3. 9.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Opportunities and Challenges
  4. 9.4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst